-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on MapLight Therapeutics, Lowers Price Target to $26

Benzinga·07/28/2026 10:19:30
Listen to the news
HC Wainwright & Co. analyst Raghuram Selvaraju maintains MapLight Therapeutics (NASDAQ:MPLT) with a Buy and lowers the price target from $45 to $26.